Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

Clinical trials for Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) explained in plain language.

Never miss a new study

Get alerted when new Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) trials appear

Sign up with your email to follow new studies for Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 2 Not yet recruiting 1

New hope for relapsed blood cancer: Three-Drug combo enters trials

Disease control Not yet recruiting

This study tests a new combination of three drugs (lisaftoclax, chidamide, and rituximab) in adults with a type of blood cancer called diffuse large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to find a safe and effective dose and see if th…

Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)

Phase 1/2 • Sponsor: Sun Yat-sen University • Aim: Disease control

Last updated Jun 27, 2026 12:36 UTC

Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

Get alerted when new Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) trials appear

New hope for relapsed blood cancer: Three-Drug combo enters trials